Literature DB >> 16458825

Peripheral neuropathy in genetic mitochondrial diseases.

David E Stickler1, Edward Valenstein, Richard E Neiberger, Leigh Ann Perkins, Paul R Carney, Jonathan J Shuster, Douglas W Theriaque, Peter W Stacpoole.   

Abstract

Peripheral neuropathy is an underrecognized but common occurrence in genetic mitochondrial disorders. To gain insight into the frequency and clinical presentation of this complication, nerve conduction studies were performed on 43 subjects with congenital lactic acidosis enrolled in a controlled clinical trial of oral dichloroacetate. Median and peroneal motor conduction studies and median and sural sensory conduction studies were performed on each patient. The mean amplitude of the peroneal motor nerve (P < 0.001) and the conduction velocities of the median (P < 0.001) and peroneal (P < 0.001) motor nerves were uniformly lower in our subjects than in healthy literature control subjects. There were no significant differences in sensory nerve conduction studies. A generalized reduction in motor nerve conduction velocity was the dominant electrophysiological abnormality in the patients in this study and was independent of age, sex, or congenital mitochondrial disorder. We postulate that cellular energy failure is the most likely common cause of peripheral neuropathy in patients with genetic mitochondrial diseases, owing to the high demand for adenosine triphosphate via aerobic carbohydrate metabolism by nerve tissue.

Entities:  

Mesh:

Year:  2006        PMID: 16458825     DOI: 10.1016/j.pediatrneurol.2005.08.006

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  9 in total

1.  The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.

Authors:  Kavi P Patel; Thomas W O'Brien; Sankarasubramon H Subramony; Jonathan Shuster; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2012-07       Impact factor: 4.797

2.  Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate.

Authors:  Albert L Shroads; Taimour Langaee; Bonnie S Coats; Tracie L Kurtz; John R Bullock; David Weithorn; Yan Gong; David A Wagner; David A Ostrov; Julie A Johnson; Peter W Stacpoole
Journal:  J Clin Pharmacol       Date:  2011-06-03       Impact factor: 3.126

3.  New mitochondrial DNA mutations in tRNA associated with three severe encephalopamyopathic phenotypes: neonatal, infantile, and childhood onset.

Authors:  María del Mar O'Callaghan; Sonia Emperador; Ester López-Gallardo; Cristina Jou; Nuria Buján; Raquel Montero; Angels Garcia-Cazorla; Diana Gonzaga; Isidre Ferrer; Paz Briones; Eduardo Ruiz-Pesini; Mercè Pineda; Rafael Artuch; Julio Montoya
Journal:  Neurogenetics       Date:  2012-05-26       Impact factor: 2.660

4.  Long-term safety of dichloroacetate in congenital lactic acidosis.

Authors:  Monica Abdelmalak; Alicia Lew; Ryan Ramezani; Albert L Shroads; Bonnie S Coats; Taimour Langaee; Meena N Shankar; Richard E Neiberger; S H Subramony; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

Review 5.  Anesthesia for children with mitochondrial disorders: a national survey and review.

Authors:  Muhammad B Rafique; Staci D Cameron; Qaiser Khan; Suur Biliciler; Salman Zubair
Journal:  J Anesth       Date:  2012-09-25       Impact factor: 2.078

6.  Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity.

Authors:  Albert L Shroads; Xu Guo; Vaishali Dixit; Hui-Ping Liu; Margaret O James; Peter W Stacpoole
Journal:  J Pharmacol Exp Ther       Date:  2007-12-20       Impact factor: 4.030

7.  Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate.

Authors:  Peter W Stacpoole; Lesa R Gilbert; Richard E Neiberger; Paul R Carney; Edward Valenstein; Douglas W Theriaque; Jonathan J Shuster
Journal:  Pediatrics       Date:  2008-04-14       Impact factor: 7.124

Review 8.  Pharmacogenetic considerations with dichloroacetate dosing.

Authors:  Margaret O James; Peter W Stacpoole
Journal:  Pharmacogenomics       Date:  2016-05-04       Impact factor: 2.533

Review 9.  Role of dichloroacetate in the treatment of genetic mitochondrial diseases.

Authors:  Peter W Stacpoole; Tracie L Kurtz; Zongchao Han; Taimour Langaee
Journal:  Adv Drug Deliv Rev       Date:  2008-07-04       Impact factor: 15.470

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.